The Prevalence and Prevention of Allergic Diseases in Postmature Infants Born to Mothers With Covid-19 Infection During Pregnancy
Keywords:
COVID-19, postmature infants, allergic diseases, immune system development, atopic dermatitis, food allergy, bronchial asthma, maternal infection, prenatal exposure, breastfeeding, probiotics, prebiotics, immunoglobulin E (IgE), eosinophiliaAbstract
This comprehensive study investigates the prevalence, clinical features, immunological mechanisms, and contributing factors of allergic diseases in postmature infants born to mothers who had contracted COVID-19 during pregnancy. In addition, it evaluates preventive and prophylactic strategies to reduce the risk of allergic manifestations in this vulnerable population. Allergic diseases, including atopic dermatitis, food allergies, urticaria, and bronchial asthma, are increasingly recognized as a major health concern in early infancy, particularly among postmature neonates whose immune, respiratory, and integumentary systems are not fully matured. These immaturities predispose the infant to heightened sensitivity to environmental, dietary, and microbial allergens, increasing the risk of both immediate and delayed hypersensitivity reactions.
The study was conducted at the Pediatric Clinics of the Faculty of Pediatrics, Tashkent State Medical University, over a period from 2022 to 2024. A total of 120 postmature infants were enrolled, divided equally into two groups: 60 infants born to mothers with confirmed COVID-19 infection during pregnancy (study group) and 60 infants born to healthy mothers without a history of COVID-19 (control group). Infants were prospectively monitored from birth until 12 months of age, employing a comprehensive set of clinical, laboratory, and immunological evaluations. These included complete blood counts with eosinophil quantification, total and specific IgE levels, skin prick and patch testing for common allergens, and detailed maternal and neonatal anamnesis, covering prenatal health, infection history, medications, feeding practices, and family allergy history.
Findings revealed that the prevalence of allergic diseases in the study group was approximately 40% compared to 20% in the control group, indicating a twofold increase in infants born to COVID-19 affected mothers. The most frequently observed conditions were atopic dermatitis (25%), food allergies (16.6%), and bronchial asthma (13.3%). Laboratory analysis indicated significantly elevated total IgE levels and eosinophil counts in the study group, suggesting a hyperactive immune response. Skin allergy testing revealed that 60% of infants in the study group exhibited sensitization to one or more allergens, compared to 25% in the control group. Additional risk factors identified included shortened duration of breastfeeding, maternal antibiotic exposure during pregnancy, early environmental allergen exposure, and maternal comorbidities.
The study emphasizes the importance of maternal health management during pregnancy, including preventive measures against COVID-19, nutritional optimization, and avoidance of unnecessary medications. Postnatally, prolonged breastfeeding, use of probiotics and prebiotics, maintenance of hygienic home environments, early allergen avoidance, and regular clinical monitoring are recommended to mitigate allergic disease development. These findings are consistent with international research highlighting the impact of maternal viral infections on fetal immune programming and the subsequent risk of allergy in early life.
This research provides a valuable reference for pediatricians, neonatologists, immunologists, and public health practitioners. It underscores the need for evidence-based preventive strategies, early clinical interventions, and public health policies to reduce the incidence and severity of allergic diseases in postmature infants born to mothers with a history of COVID-19. Furthermore, it contributes to a growing body of literature regarding the long-term implications of prenatal viral infections on child health and supports the development of targeted immunomodulatory and nutritional interventions. The study advocates for the integration of maternal-infant health monitoring programs, allergy prevention protocols, and educational campaigns to enhance awareness of allergy risk and early intervention strategies.
References
1. Walker, M. (2017). Why we sleep: Unlocking the power of sleep and dreams. Scribner.
2. Siegel, J. M. (2005). Clues to the functions of mammalian sleep. Nature, 437(7063), 1264–1271.
3. Institute of Medicine (US) Committee on Sleep Medicine and Research. (2006). Sleep disorders and sleep deprivation: An unmet public health problem. National Academies Press.
4. Opp, M. R., & Spiegel, K. (2009). Sleep and immunity. Sleep Medicine Reviews, 13(5), 279–290.
5. Li, Y., et al. (2015). Effects of sleep deprivation on immune response. Sleep Science, 8(3), 109–114.
6. Brough, H. A., et al. (2018). The influence of maternal diet on infant allergy development. Clinical & Experimental Allergy, 48(3), 243–255.
7. Prescott, S. L. (2013). Early-life environmental determinants of allergic diseases and the wider pandemic of noncommunicable diseases. Journal of Allergy and Clinical Immunology, 131(1), 23–30.
8. Fiocchi, A., et al. (2010). Food allergy: Causes, mechanisms, and treatment. World Allergy Organization Journal, 3(9), 257–266.
9. Sicherer, S. H., & Sampson, H. A. (2014). Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment. Journal of Allergy and Clinical Immunology, 133(2), 291–307.
10. Wang, J., et al. (2020). Maternal COVID-19 infection and neonatal outcomes: A systematic review. Frontiers in Pediatrics, 8, 616.
11. Chen, H., et al. (2020). Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in pregnant women. The Lancet, 395(10226), 809–815.
12. Dong, L., et al. (2020). Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn. JAMA, 323(18), 1846–1848.
13. Rasmussen, S. A., et al. (2020). Coronavirus disease 2019 (COVID-19) and pregnancy: What obstetricians need to know. American Journal of Obstetrics and Gynecology, 222(5), 415–426.
14. Knight, M., et al. (2020). Characteristics and outcomes of pregnant women hospitalized with confirmed SARS-CoV-2 infection in the UK. BMJ, 369, m2107.
15. Zhang, L., et al. (2021). Maternal COVID-19 infection and risk of allergic diseases in infants: A cohort study. Pediatric Allergy and Immunology, 32(2), 281–289.
16. Yang, H., et al. (2021). Maternal viral infections and postnatal immune development. Frontiers in Immunology, 12, 638669.
17. Kozyrskyj, A. L., et al. (2007). Maternal infection during pregnancy and infant atopic disease. Allergy, 62(2), 205–212.
18. Kull, I., et al. (2006). Early-life environmental exposures and allergic sensitization. Journal of Allergy and Clinical Immunology, 118(5), 1134–1141.
19. Fieten, K. B., et al. (2021). Postmature infants and risk of allergic disease development. Pediatrics, 147(6), e2020019751.
20. D’Souza, R., et al. (2018). The role of the maternal immune system in fetal development. Nature Reviews Immunology, 18(10), 635–650.
21. Prescott, S. L., & Björkstén, B. (2007). Early-life immune development and allergic disease prevention. Current Opinion in Allergy and Clinical Immunology, 7(2), 124–130.
22. Brandtzaeg, P. (2010). The mucosal immune system and its integration with the mammary glands. Journal of Pediatrics, 156(2), S8–S15.
23. Tait, S., et al. (2013). Breastfeeding and immune system development in infants. Journal of Human Lactation, 29(3), 361–370.
24. Renz, H., et al. (2011). Development of allergic diseases: Role of maternal and environmental factors. Allergy, 66(5), 659–666.
25. Fiocchi, A., et al. (2012). Prevention of allergic diseases: A review. World Allergy Organization Journal, 5(9), 1–14.
26. West, C. E., et al. (2016). Probiotics in allergy prevention: Mechanisms and evidence. Current Opinion in Allergy and Clinical Immunology, 16(5), 513–520.
27. Vandenplas, Y., et al. (2020). Use of probiotics in infants: Impact on allergy development. Nutrients, 12(3), 840.
28. Lin, Y., et al. (2021). Effect of maternal COVID-19 infection on infant immune profile. Clinical Immunology, 228, 108740.
29. Sun, X., et al. (2020). Maternal SARS-CoV-2 infection and fetal immunoglobulin transfer. Frontiers in Immunology, 11, 576778.
30. Chua, M. S., et al. (2016). Postmature infant morbidity and immune system evaluation. Pediatric Research, 79(5), 727–734.
31. Meltzer, D. O., et al. (2020). COVID-19 and pregnancy: Epidemiology, risk factors, and outcomes. Journal of Clinical Medicine, 9(9), 2722.
32. Sun, J., et al. (2021). Maternal infection and allergic disease in offspring: Systematic review. Allergy, Asthma & Immunology Research, 13(5), 699–713.
33. Liu, Y., et al. (2021). Postnatal immune responses in infants born to COVID-19 infected mothers. Pediatric Allergy and Immunology, 32(7), 1463–1472.
34. Chen, S., et al. (2021). Maternal COVID-19 and infant IgE and eosinophil levels. Journal of Pediatric Immunology, 13(4), 205–216.
35. Zhang, R., et al. (2022). Allergic disease prevalence in postmature infants: 5-year study. BMC Pediatrics, 22, 45.
36. Zhao, Y., et al. (2021). Influence of maternal viral infection on neonatal immunity. Frontiers in Pediatrics, 9, 669874.
37. Ismail, L. C., et al. (2012). Environmental exposures and allergic sensitization in infants. Allergy, 67(6), 765–774.
38. Hanson, L. A. (2007). Breastfeeding and immune development in the neonate. Journal of Nutrition, 137(2), 442S–447S.
39. Arrieta, M.-C., et al. (2014). Early infant microbial exposure, gut microbiome, and immune development. Pediatric Research, 75(1–2), 242–249.
40. Korpela, K., et al. (2016). Probiotic supplementation and prevention of allergic diseases. Journal of Allergy and Clinical Immunology, 137(2), 564–571.
